Form 4: Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, Executes Stock Option and Sells Shares

Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On May 6, 2025, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, Inc., engaged in transactions involving the company's stock.
• Rolph exercised stock options to acquire 12,500 shares of common stock at a price of $21.10 per share.
• Concurrently, Rolph sold 3,550 shares at a weighted average price of $42.264, 8,650 shares at a weighted average price of $43.87, and 300 shares at a weighted average price of $44.503.
• These transactions were executed under a pre-existing Rule 10b5-1 trading plan adopted on August 12, 2024.
• Following these transactions, Rolph directly owns 169,721 shares of Akero Therapeutics common stock and 12,889 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in compliance with SEC regulations.
• The Rule 10b5-1 trading plan is a common tool used by corporate insiders to sell shares while avoiding accusations of insider trading, similar to practices at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• Shareholders may interpret the stock sales as a lack of confidence by the executive, although the pre-arranged trading plan mitigates this concern.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Akero Therapeutics, Timothy Rolph, stock options, Rule 10b5-1, insider trading, Form 4, AKRO, Chief Scientific Officer, stock sale